[go: up one dir, main page]

TW200904811A - Use of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester for preparing the tryptase inhibitor [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone - Google Patents

Use of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester for preparing the tryptase inhibitor [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone Download PDF

Info

Publication number
TW200904811A
TW200904811A TW097111154A TW97111154A TW200904811A TW 200904811 A TW200904811 A TW 200904811A TW 097111154 A TW097111154 A TW 097111154A TW 97111154 A TW97111154 A TW 97111154A TW 200904811 A TW200904811 A TW 200904811A
Authority
TW
Taiwan
Prior art keywords
methyl
thiophene
bromo
propoxy
carboxylic acid
Prior art date
Application number
TW097111154A
Other languages
Chinese (zh)
Inventor
Ann Marie Gelormini
John J Shay
Adam W Sledeski
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of TW200904811A publication Critical patent/TW200904811A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention is directed to a five step regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid compound of formula 16 comprising the steps of acetalating 3-methyl-thiophene-2-carbaldehyde in an alcohol solvent; iodinating the acetalated 3-methyl-thiophene-2-carbaldehyde in an non-protic polar or hydrocarbon solvent to yield the corresponding iodinated and acetalated 3-methyl-thiophene-2-carbaldehyde product; treating the iodinated and acetalated product with water to yield the corresponding 5-iodo-3-methyl-thiophene-2-carbaldehyde; oxidizing the 5-iodo-3-methyl-thiophene-2-carbaldehyde to the corresponding 5-iodo-3-methyl-thiophene-2-carboxylic acid in ketone solvent; Ullmann coupling of the 5-iodo-3-methyl-thiophene-2-carboxylic acid with alkali metal propoxide salt using a copper catalyst in propanol to yield 3-methyl-5-propoxy-thiophene-2-carboxylic acid; esterifying 3-methyl-5-propoxy-thiophene-2-carboxylic acid to yield the corresponding alkyl 3-methyl-5-propoxy-thiophene-2-carboxylate; brominating the 3-methyl-5-propoxy-thiophene-2-carboxylic acid to yield the corresponding alkyl 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylate; and basic hydrolyzing the alkyl 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylate with base to yield 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid.

Description

200904811 九、發明說明: 【發明所屬之技術領i或j 本發明涉及4,_3_甲基—5 氧吡咯烷-1-基酯在製備類姨 '^°蕃吩_2·鲮酸2,5-二 術基)-六氮㈣:基;;= 基)-曱酮過程中作為中間體的用途。Α _5_丙减°塞吩I 【先前技術】 W02001/13811被露了—此^卜入此 ^ 趿路ί些化合物,包括作為類胰蛋白 酶抑制劑的[(苯曱胺)-六氫吼咬小基](芳基或雜芳基)甲 酮,並敘述了因類胰蛋白酶涉及各種生物過程包括使血管 舒張和支氣管鬆弛的神經肽的降解過程(Caughey, et al.,j.200904811 IX. Description of the invention: [Technology of the invention] i or j The present invention relates to 4,_3_methyl-5 oxapyrrolidin-1-yl ester in the preparation of 姨'^° 吩 _2 鲮 鲮 鲮 2 5-Actyl)-hexanitro(tetra):yl;;=yl)-indoleone as an intermediate in the process. _ _5_丙减 ° 塞11 I [Prior Art] W02001/13811 was exposed - this ^ 入 ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ Biting a small base] (aryl or heteroaryl) ketone, and describes the degradation process of neuropeptides involved in various biological processes including tryptase and bronchial relaxation by tryptase (Caughey, et al., j.

Pharmacol. Exp. Ther., 1988, 244, pages 133-137; Franconi, et al” J. Pharmacol. Exp. Ther·, 1988, 248, pages 947-951 ;以 i5 及 Tam, et al.,Am. J. Respir. Cell Mol. Biol” 1990, 3, pages 27-32)以及對於支氣管一組胺反應性的調節過程(Sekizawa, etal.,J. Clin. Invest., 1989, 83, pages 175-179),從而決定的 這類化合物的潛在用途。 W02005/097780更具體地彼露了結構式為A的(苯曱 2〇 胺)-六氫η比咬-1-基噻吩基甲酮化合物’即([4-(5-胺基甲基-2- 氟苯基)-六氫°比咬-1-基]-(4-溴-3-曱基-5-丙氧基嗟吩-2-基)-甲酮), 200904811Pharmacol. Exp. Ther., 1988, 244, pages 133-137; Franconi, et al" J. Pharmacol. Exp. Ther., 1988, 248, pages 947-951; i5 and Tam, et al., Am. J. Respir. Cell Mol. Biol” 1990, 3, pages 27-32) and the regulation of a group of amine reactivity in the bronchus (Sekizawa, et al., J. Clin. Invest., 1989, 83, pages 175-179) ), thereby determining the potential use of such compounds. W02005/097780 more specifically discloses a (benzoquinone 2 decylamine)-hexahydron-by-l-ylthienyl ketone compound of the formula A (ie ([4-(5-aminomethyl)- 2-fluorophenyl)-hexahydropyranyl-1-yl]-(4-bromo-3-indolyl-5-propoxyindol-2-yl)-methanone, 200904811

它的製備方法,及其在可通過抑制類胰蛋白酶而治療的疾 病方面的用途。W02005/ 097780還披露,結構式為A的化 合物是通過下述化合物16與10的偶合反應,以及偶合產 物隨後的脫保護反應而製備的,如下所示Its preparation method and its use in diseases which can be treated by inhibiting tryptase. W02005/097780 also discloses that the compound of formula A is prepared by the coupling reaction of the following compounds 16 and 10, and the subsequent deprotection of the coupling product, as shown below.

中間體化合物16是按照下述多步驟製備法製備的 200904811Intermediate compound 16 was prepared according to the following multi-step preparation method 200904811

NaH KOH cs2 o 人 41%NaH KOH cs2 o person 41%

M©ONa 86% ¢11-13)M©ONa 86% ¢11-13)

MeOHI 77%MeOHI 77%

雖然通過上述過程也能製備中間體16,但它採用了繁 多的步驟,採用了氣味特徵令人不快的無環中間體,而且 不是從易得的噻吩基原料開始製備。此過程在化合物15的 , 酯基向化合物16中對應的酸基轉化的過程中,需要一個額 外的步驟,例如,操縱化合物16中間體中的羧基功能團。 本發明涉及類胰蛋白酶抑制劑[4-(5-胺基曱基-2-氟苯 基)-六鼠吼σ定-1 -基]_(4_>臭-3 -甲基-5-丙氧基σ塞吩-2-基)-甲酉同 的製備方法,其包括以下步驟: ίο 使4-溴-3-曱基-5-丙氧基η塞吩-2-竣酸2,5-二氧σ比咯烧 -1 -基酯與2,2,2-三氟-N-(4-氟-3-六氫吡啶-4-基苯曱 基)-乙醯胺鹽酸鹽和強鹼或叔胺鹼在醇溶劑中發生醯 200904811 知化偶合反應,以生成2 ? ?-知 战 2,2,2_二鼠-Ν-{3-Π-(4-溴各甲 二,乳基嗟吩-2·幾基)_六氫❿定_4_基]_4_氣_ 基}-乙醯胺;以及 用驗使2,2,2-三氟-N-{3-fW4、、皇1田且《工ρ # ^ P 臭_3_甲基-5-丙氧基噻吩 基)-六氫吼基]·4|苯甲基卜乙醯胺脫保 幻以生成[4-(5-胺基曱基_2_氣苯基)_六4吼唆小 基]-(4-演-3-曱基-5-丙氧基噻吩_2_基)_甲酮。 【發明内容】 通過參閱以下詳細說明將能更理解本發明。 定義 如上文所用以及貫穿本發明之全部說明,包括所附的 申凊專利範圍,下列縮寫和術語應被理解為具有以下含 15 義,除非另行說明: 「驗金屬」意為鐘、鈉、鉀或|色。 「驗金屬丙醇鹽」意為通過用一種強鹼處理丙烷而得 到的一種鹽的形式。強鹼的例子有Cs2C03,鹼金屬的鹼如 NaH、NaHMDS、KHMDS、LiHMDS、二異丙醯胺鋰(LDA), 20 或烷基金屬如烷基鋰、烷基鉀、烷基鈉以及烷基鎂’其中 的烷基是CN5烷基,更為首選的是丁基’例如、Cs0Pr、 NaOPr、LiOPr 或 KOPr。 「醯胺化偶合」意為生成一種醯胺的偶合反應。 「溴化劑」意為一種溴源’例如Br2或° 200904811 「 铜催化劑」意為一種能促進烏爾曼偶合反應的鋼催 化劑’選自 CuSCN、CuBr、Cul、CuCU、CuBF4、CuPF6、 Cu〇Tf、CuPF6、CuBr2、CuCl2、和 Cu20。 偶合助溶劑」意為能與丙烷偶合溶劑聯合使用的另 種惰性有機溶劑,例如THF、甲苯、2·甲基THF,或-甲氧基乙烷。 「酿化」意為從羧酸基向其對應酯的轉化。 偶合劑」意為一種選自CDI、DCC、PFP、HOBT和 HBTU等用於實現g旨化反應的化合物。 "水解助溶劑」意為一種惰性極性有機溶劑,例如一 種醚如1,4-二噁烧、叔丁基曱基醚仰剛、異丙基乙基醚 以及二乙喊。 、「鹼性水解」意為使用鹼金屬的氫氧化物例如鋰、鈉 或鉀的氫氧化物或鹼土金屬的氫氧化物以實現水解。 y碘化劑」意為ι2、二碘乙烯、ια,或NBI。 1 ^化」意為在—種強驗存在條件下與—種峨化劑進 非質子極性溶劑」意為 基曱基醚(TBME)、異丙基乙基 二氧戊烷等。 一種溶劑,例如乙醚、叔丁 趟、THF、1,4-二噁烷或n 烴 3 = 2為,溶劑例如甲苯、二甲苯或庚燒等。 例如氯仿或二氯甲燒。3 首相疋氣或氣)代 「惰性溶劑」意為—種非f子極性溶劑、烴溶劑、齒 200904811 代烴溶劑、腈類溶劑如乙腈,或有機酸溶劑如乙酸或丙酸。 「強鹼」意為一種鹼金屬的鹼,例如NaH、NaHMDS、 KHMDS、LiHMDS、二異丙醯胺鋰(LDA),或烷基金屬鹼, 例如院基裡、烧基鉀、烧基納和烧基鎮,其中該炫基是Cu 5 脂環烷基(直鏈的、支鏈的或環烷基),更為首選的是丁基。 「叔胺鹼」意為一種CN5有機鹼,其中的氮不帶氫原 子,例如三乙胺。 【實施方式】 10 在依知本發明之方法的一個具體實施例中’蛾化是在 THF中實現的。 在依照本發明之方法的另一具體實施例中,碘化所用 的強驗是LDA。 在依照本發明之方法的另一具體實施例中’碘化劑是 15 工2。 在依照本發明之方法的另一具體實施例中,碘化是於 約-80°C至約0。(:的溫度條件下實現的。 在依照本發明之方法的另一具體實施例中,鹼金屬丙 醇鹽是NaOPr。 20 在依照本發明之方法的另一具體實施例中’銅催化劑 是 Cul。 在依照本發明之方法的另一具體實施例中’取決於所 用溶劑和所用壓力,偶合反應是於約70°C至約120°C的加 熱條件下實現的。 -12- 200904811 在依照本發明之方法的另一具體實施例中,與co2的 偶合反應所用的溶劑是THF。 在依照本發明之方法的另一具體實施例中,與C02的 偶合反應所用的強鹼是正丁基鋰。 5 在依照本發明之方法的另一具體實施例中,與C02的 偶合反應是在低於-14°C溫度條件下進行的,更首選的溫度 是從約-22°C至約-14°C。 在依照本發明之方法的另一具體實施例中,用於酯化 的溶劑是二氣曱烷。 ίο 在依照本發明之方法的另一具體實施例中,用於酯化 的偶合劑是羰基二咪唑。 在依照本發明之方法的另一具體實施例中,酯化是於 約為室溫的條件下進行的。 在依照本發明之方法的另一具體實施例中,溴化用的 15 惰性溶劑是鹵代烴;更為首選的是二氣曱烷。 在依照本發明之方法的另一具體實施例中,溴化是於 約0°C至約100°C的溫度條件下實現的。 在依照本發明之方法的另一具體實施例中,溴化劑是Although the intermediate 16 can be prepared by the above process, it employs a wide variety of steps, using an acyclic intermediate having an unpleasant odor characteristic, and is not prepared from a readily available thiophene-based starting material. This process requires an additional step in the conversion of the ester group of compound 15 to the corresponding acid group in compound 16, for example, manipulation of the carboxyl functional group in the intermediate of compound 16. The present invention relates to a tryptase inhibitor [4-(5-aminomercapto-2-fluorophenyl)-hexarum oxime-1 -yl]-(4_>odor-3-methyl-5-propyl A method for the preparation of oxy σ sept-2-yl)-formamidine, which comprises the steps of: ίο 4-bromo-3-indolyl-5-propoxy η-cephen-2-pyruic acid 2,5 -Dioxo-pyrrolidene-1 -yl ester and 2,2,2-trifluoro-N-(4-fluoro-3-hexahydropyridin-4-ylphenylhydrazino)-acetamide hydrochloride and A strong base or a tertiary amine base undergoes an intellectual coupling reaction of 醯200904811 in an alcohol solvent to form 2?-- 2,2,2_2 mice-Ν-{3-Π-(4-bromo-methyl-, Milky porphin-2·singyl)_hexahydroindole _4_yl]_4_qi_yl}-acetamide; and using 2,2,2-trifluoro-N-{3-fW4 ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, -(5-Aminoguanidino-2-ylphenyl)-hexa-4-indenyl]-(4-o-3-indol-5-propoxythiophen-2-yl)-methanone. SUMMARY OF THE INVENTION The present invention will be more fully understood from the following detailed description. DEFINITIONS As used above and throughout the description of the invention, including the scope of the appended claims, the following abbreviations and terms are understood to have the following meanings unless otherwise stated: "Metal" means bell, sodium, potassium Or | color. "Test metal alkoxide" means a form of a salt obtained by treating propane with a strong base. Examples of strong bases are Cs2C03, alkali metal bases such as NaH, NaHMDS, KHMDS, LiHMDS, lithium diisopropylamide (LDA), 20 or alkyl metal such as alkyl lithium, alkyl potassium, sodium alkyl and alkyl. The alkyl group of the magnesium ' is a CN5 alkyl group, and more preferably a butyl group such as Cs0Pr, NaOPr, LiOPr or KOPr. "Amidoxime coupling" means the formation of a coupling reaction of guanamine. "Bromide" means a bromine source 'eg Br2 or ° 200904811 "Copper catalyst" means a steel catalyst capable of promoting the Ullmann coupling reaction 'selected from CuSCN, CuBr, Cul, CuCU, CuBF4, CuPF6, Cu〇 Tf, CuPF6, CuBr2, CuCl2, and Cu20. Coupling cosolvent means another inert organic solvent such as THF, toluene, methyl THF or -methoxyethane which can be used in combination with a propane coupling solvent. "Brewing" means the conversion from a carboxylic acid group to its corresponding ester. "Coupling agent" means a compound selected from the group consisting of CDI, DCC, PFP, HOBT, and HBTU for effecting the g reaction. "hydrolyzed cosolvent" means an inert polar organic solvent such as an ether such as 1,4-dioxin, tert-butyl decyl ether, isopropyl ethyl ether and diethyl sulfonate. "Alkaline hydrolysis" means the use of an alkali metal hydroxide such as a hydroxide of lithium, sodium or potassium or a hydroxide of an alkaline earth metal to effect hydrolysis. By y iodinating agent is meant ι 2, diiodoethylene, ια, or NBI. "1" means "in the presence of a strong test condition and a deuterated agent into an aprotic polar solvent" means benzyl ether (TBME), isopropylethyldioxane, and the like. A solvent such as diethyl ether, tert-butyl hydrazine, THF, 1,4-dioxane or n hydrocarbon 3 = 2 is a solvent such as toluene, xylene or heptane. For example, chloroform or methylene chloride. 3 Prime Minister Helium or Gas) "Inert solvent" means a non-f-polar solvent, hydrocarbon solvent, tooth 200904811 hydrocarbon solvent, nitrile solvent such as acetonitrile, or organic acid solvent such as acetic acid or propionic acid. "Strong base" means an alkali metal base such as NaH, NaHMDS, KHMDS, LiHMDS, lithium diisopropylamide (LDA), or an alkyl metal base such as a hospital base, a potassium base, a succinyl group, and An alkyl group in which the leuco is a Cu 5 alicyclic alkyl group (linear, branched or cycloalkyl), more preferably a butyl group. "Terminal amine base" means a CN5 organic base in which the nitrogen does not have a hydrogen atom such as triethylamine. [Embodiment] 10 In a specific embodiment of the method of the present invention, the mothization is carried out in THF. In another embodiment of the method according to the invention, the test used for iodination is LDA. In another embodiment of the method according to the invention the 'iodinating agent is 15 work 2 . In another embodiment of the method according to the invention, the iodination is from about -80 ° C to about 0. In another embodiment of the method according to the invention, the alkali metal propoxide is NaOPr. 20 In another embodiment of the method according to the invention, the 'copper catalyst is Cul In another embodiment of the method according to the invention 'depending on the solvent used and the pressure employed, the coupling reaction is effected under heating from about 70 ° C to about 120 ° C. -12- 200904811 In another embodiment of the process of the invention, the solvent used in the coupling reaction with co2 is THF. In another embodiment of the process according to the invention, the strong base used in the coupling reaction with CO 2 is n-butyllithium. 5 In another embodiment of the method according to the invention, the coupling reaction with CO 2 is carried out at a temperature below -14 ° C, and more preferably from about -22 ° C to about -14 ° C. In another embodiment of the method according to the invention, the solvent used for the esterification is dioxane. ίο In another embodiment of the method according to the invention, the coupling agent for esterification Is carbonyl diimidazole. In another embodiment of the method of the invention, the esterification is carried out at about room temperature. In another embodiment of the process according to the invention, the 15 inert solvent for bromination is a halogenated hydrocarbon More preferred is dioxane. In another embodiment of the method according to the invention, bromination is effected at a temperature of from about 0 ° C to about 100 ° C. In accordance with the invention In another embodiment of the method, the brominating agent is

Br2。 20 在依照本發明之方法的另一具體實施例中,醯胺化偶 合所用的醇溶劑是乙醇。 在依照本發明之方法的另一具體實施例中,醯胺化偶 合是於約室溫至約30°C的溫度條件下實現的。 在依照本發明之方法的另一具體實施例中,醯胺化偶 -13- 200904811 合所用的鹼是三乙胺。 在依照本發明之方法的另一具體實施例中,脫保護反 應是用驗的水溶液、NaOH水溶液實現的。 在依照本發明之方法的另一具體實施例中,脫保護反 應是於約5°C至約30°C的溫度條件下實現的。 實例 製備細節 原料可以購入或通過應用或改進已知的方法來製備, 10 或利用它們顯然的化學等效物。 通過參考以下本發明典型的非限制性實例,本發明可 更好地得到理解。提供以下實例是為了更充分地說明本發 明的具體實施例。然而,它們無論如何不應被理解為是限 制本發明的寬廣範圍。 is 在下文列出的核磁共振光譜(NMR)中,化學位移以 ppm表示,以四甲基矽烷為内標。諸縮寫具有下列含義:br =寬峰,dd=雙峰,s =單峰;m=多重峰。 以下實例中所述的4-溴-3-甲基-5-丙氧基噻吩-2-羧酸 2,5-二氧吡咯烷-1-基酯的合成可以如下示意圖I表示。 -14- 20 200904811 示意圖i /\^ONaBr2. In another embodiment of the method according to the invention, the alcohol solvent used for the amidoximation is ethanol. In another embodiment of the method according to the invention, the guanidine coupling is effected at a temperature of from about room temperature to about 30 °C. In another embodiment of the process according to the invention, the base used in the amilylation coupling -13-200904811 is triethylamine. In another embodiment of the method according to the invention, the deprotection reaction is carried out using an aqueous solution of the test, aqueous NaOH. In another embodiment of the method according to the invention, the deprotection reaction is effected at a temperature of from about 5 ° C to about 30 ° C. EXAMPLES Preparation Details Raw materials can be purchased or prepared by applying or modifying known methods, 10 or using their apparent chemical equivalents. The invention may be better understood by reference to the following non-limiting examples of the invention. The following examples are provided to more fully illustrate the specific embodiments of the invention. However, they should not be construed as limiting the broad scope of the invention in any way. Is In the nuclear magnetic resonance spectroscopy (NMR) listed below, the chemical shift is expressed in ppm and tetramethyl decane is used as an internal standard. The abbreviations have the following meanings: br = broad peak, dd = doublet, s = singlet; m = multiplet. The synthesis of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxapyrrolidin-1-yl ester described in the following examples can be represented by the following scheme I. -14- 20 200904811 Schematic i /\^ONa

實例1 : 2-碘-4-曱基噻吩 5 向一個設有頂部攪拌器、橡膠隔膜、熱電偶以及氮氣 進/出口的3升4頸燒瓶加入3-曱基π塞吩(135 mL,1.38 mol) 和THF(1 L)。將該混合物冷卻至-20°C並通過12號(12 gauge) 導管在一段35分鐘的時間内加入LDA(800 mL溶於THF/ 庚烷/乙苯的Aldrich 2.5 Μ溶液),調節添加速率並根據必 ίο 要冷卻,以將反應溫度維持在-25°C和-15°C之間。添加結 束後,將該混合物攪拌30分鐘,將溫度維持在0 °C以下。 在另一設有頂部攪拌器、冷浴、氮氣流和熱電偶的5 L 升燒瓶中,將碘(454 g,1.3當量)溶於THF(1.65 L),於室 溫攪拌20分鐘以確保完全溶解並冷卻至-20°C。當溶液冷 -15 - 200904811 卻至-10°C時,碘開始析出。 讓該陰離子溶液升溫至〇cC並通過導管在4〇分鐘期間 加入碘的溶液,根據需要調節添加速率以將反應溫度維4 在-15°C或以下。當添加結束時,讓該混合物於2小時内升 5 溫至l〇°C。將反應物用MTBE(1.0 L)稀釋並用半飽和氣化 銨(500 mL)終止反應。用0.5 N硫代硫酸鈉(2 x 75〇 mL)、2 X 1 L水(2x 1 L)和鹽水(200 mL)洗滌有機層。任有機層在一 分離器内靜止4小時並抽出所有分離出的水。將有機層於 30°C和175 mbar的條件下通過旋轉蒸發而濃縮至12 l。 10 HPLC分析在水相或餾出液内基本上均未測出產物。少量和 無法疋塁的未反應3-曱基嗟吩在洗條和蒸發過程中失去。 根據回收的原料、不合格異構體的形成,以及洗滌液或旋 轉蒸發顧出液中均不存在產物的事實,出於估計烏爾曼偶 合反應試劑的目的,計算出此反應的產率為73%。 15 H 丽R(CDCl3 ’ §)7.05(出,密集多重峰),(6.91(1H,密集 多重峰)),(2.21,3H,。 實例2 . 4-曱基-2-丙氧基n塞吩 在σ又有L女斯達克分水器(Dean-Stark trap)以及頂部 2。 目流式冷凝H 1部_器、液上空間熱電偶以及氮氣進/ 出口的3升3頌燒瓶中,將實例丨所得溶液1.2 L與正丙烧 (1 將。亥扣合物加熱至回流並抽出餾出液,並用正 丙炫部分置換(約除去1.2 L並加入500 mL正丙烧)直至液 上工間,皿度達到96。(:。將該混合物冷卻至5〇〇c並加入固 •16· 200904811Example 1: 2-Iodo-4-mercaptothiophene 5 To a 3-liter 4-neck flask equipped with an overhead stirrer, a rubber septum, a thermocouple, and a nitrogen inlet/outlet, 3-mercapto π-cetin (135 mL, 1.38) was added. Mol) and THF (1 L). The mixture was cooled to -20 ° C and LDA (800 mL of Aldrich 2.5 溶于 solution in THF / heptane / ethylbenzene) was added over a 35-minute period over a 12 gauge tube to adjust the rate of addition and Cool down to maintain the reaction temperature between -25 ° C and -15 ° C. After the addition was completed, the mixture was stirred for 30 minutes and the temperature was maintained below 0 °C. In a 5 L liter flask equipped with an overhead stirrer, cold bath, nitrogen stream and thermocouple, iodine (454 g, 1.3 eq.) was dissolved in THF (1.65 L) and stirred at room temperature for 20 min to ensure completeness Dissolve and cool to -20 °C. When the solution was cold -15 - 200904811 but reached -10 ° C, iodine began to precipitate. The anion solution was allowed to warm to 〇cC and a solution of iodine was added through the catheter over a period of 4 minutes, and the rate of addition was adjusted as needed to bring the reaction temperature dimension to -15 ° C or below. When the addition was complete, the mixture was allowed to warm to 5 °C over 2 hours. The reaction was diluted with MTBE (1.0 L) and quenched with semi-saturated ammonium sulfate (500 mL). The organic layer was washed with 0.5 N sodium thiosulfate (2 x 75 mL), 2×1 L water (2×1 L) and brine (200 mL). The organic layer was allowed to stand in a separator for 4 hours and all of the separated water was withdrawn. The organic layer was concentrated to 12 l by rotary evaporation at 30 ° C and 175 mbar. 10 HPLC analysis essentially no product was detected in either the aqueous phase or the distillate. A small amount of unreacted 3-indolyl porphin is lost during washing and evaporation. Based on the recovered raw materials, the formation of the unqualified isomers, and the fact that no product is present in the washing liquid or the rotary evaporation solvent, the yield of the reaction is calculated for the purpose of estimating the Ullmann coupling reagent. 73%. 15 H R (CDCl3 ' §) 7.05 (out, dense multiplet), (6.91 (1H, dense multiplet)), (2.21, 3H,. Example 2. 4-mercapto-2-propoxy n-plug In the σ, there is a Dean-Stark trap and a top 2. A flow-through condensing H 1 part, a liquid space thermocouple, and a nitrogen inlet/outlet in a 3 liter 3 颂 flask. Example 丨 丨 丨 丨 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 In the work room, the degree of the dish reached 96. (:. The mixture was cooled to 5〇〇c and added to the solid•16·200904811

體叔丁醇鈉(192 g ’ 2 mol,約2當量),放熱導致升溫至約 75 °C。將該混合物維持在75和85。(:之間,直至所有固體 全部溶解。再將反應混合物冷卻至5〇°C,加入剛製備的碘 化銅〗(100 mmo卜19 g)在正丙烷(50 ml)中的漿料。將該混合 物加熱至95。(:。達到反應溫度30分鐘後HPLC分析顯示 反應已完全。用庚燒(1 L)稀釋該混合物。加入石夕藻土(190 g),將生成的漿料攪拌60分鐘同時冷卻至室溫。過濾該混 合物並用庚烷(500 mL)洗滌濾餅。依次用5%EDTA二鈉水 溶液(3 X 500 mL)、水(3 X 500 mL)和鹽水(500 mL)洗滌該濾 液和洗滌液,即得一顏色很深的有機層,將其濃縮至<2〇〇 mL(170mbar’ 60。〇,即得 l59g 深棕色液體,以 iHNMR 分析即為51A%所需的化合物。主要的雜質是庚烷、乙苯(來 自於購入的LDA)及2-碘-3-曱基噻吩。 H NMR(CDC13 ’ δ) 6·18(1Η,d) ; 6.02(1H,d) ; 3.98(2H, t),2,15(3H ’ S) ; 2·80(2Η ’ m) ; l_〇5(3H,t)。 實例3 : 3-曱基-5-丙氧基嘆吩_2_緩酸 將實例2的粗製4_甲基w氧基料(計算值 20 =轉移至設有頂部攪拌、熱電偶、氣氣進口/出口,壓 力平衡滴液漏斗和橡膠隔膜的2井3Sodium tert-butoxide (192 g '2 mol, ca. 2 equivalents) exothermed to raise the temperature to about 75 °C. The mixture was maintained at 75 and 85. (Between: until all solids were dissolved. The reaction mixture was cooled to 5 ° C and a freshly prepared copper iodide (100 mmo 19 g) slurry in n-propane (50 ml) was added. The mixture was heated to 95. (: After HPLC reaction was carried out for 30 minutes, HPLC analysis showed the reaction was completed. The mixture was diluted with heptane (1 L). Shishizao soil (190 g) was added, and the resulting slurry was stirred 60. The mixture was cooled to room temperature at the same time. The mixture was filtered and the filter cake was washed with heptane (500 mL), washed sequentially with 5% aqueous EDTA solution (3 X 500 mL), water (3 X 500 mL) and brine (500 mL) The filtrate and the washing liquid obtained a dark organic layer, which was concentrated to < 2 〇〇 mL (170 mbar' 60 〇, which gave a pale brown liquid of 159 g, which was required to be 51 A% by iH NMR analysis. The main impurities are heptane, ethylbenzene (from purchased LDA) and 2-iodo-3-mercaptothiophene. H NMR (CDC13 ' δ) 6.18 (1Η, d); 6.02 (1H, d ; 3.98(2H, t), 2,15(3H ' S) ; 2·80(2Η ' m) ; l_〇5(3H,t). Example 3: 3-mercapto-5-propoxy Sighing _2_slow acid will be the crude 4_A of Example 2 w feed group (calc = 20 is transferred to the top with stirring, thermocouple, gas gas inlet / outlet, a pressure equalizing dropping funnel and a rubber septum 2 Well 3

THF稀釋。將該混合物冷卻至·22= f堯瓶中,並用刪mL mW.4當量)的庚烧溶液通過加料漏正丁絲(撕 方式迅速加人,溫度範圍為_22至二。'在16分鐘内以滴加 1硬化銅是在研缽中剛研磨的並以正丙醇聚 -17-的形式趟聲處理5 14 c ’穩定在約-21°C。 分鐘 200904811 30分鐘後’將溫度維持在七〇c卩下,反應混合物 析(經d2〇淬熄)顯示約96%鐘化。將二氧化碳鼓入該混: 物,控制氣體流罝以維持反應溫度低於_丨5。c。繼續添加C 〇 直至不再放熱且反應溫度開始下降。用氮氧化納H2 5 液(_ mL)終止反應並加入石夕藻土(50 g)。將該混合物授拌 30分鐘並用遽布過滤。用0.5 #氫氧化納(3〇叫洗務據餅。 合併遽液和洗驗後得-深棕色溶液,職郎x2〇〇mL) 洗條。將水相pH值調節至約為6 8,此時形成枯稠狀標色/ 黑色焦油。將該溶液用據布過遽,即得一淡掠色滤液。將 ,〇 PH值繼績調節至4.5 ’即得大量棕色沉殿,用濾、布過渡, 用冰水(10 0 m L)洗務’在玻璃器皿内風乾再用真空煤箱乾燥 (12小時’ 30〇C ’ 1.3 mbar) ’即得3_甲基_5_丙氧基。塞吩_2_ 羧酸,為米黃色固體(81.1 g,80〇/〇)。 ^NMRCCDCh &gt; δ)6.12(1Η &gt; s) ; 4.02(3H &gt; t) ; 2.49(3H » s); is 1·82(2Η,m) ; 1.05(3H,t)。 實例4 : 3-曱基-5-丙氧基嗟吩_2嚷酸2,5_二氧吼咯烧」基 酯 在設有頂部赫、冷洛、熱電偶和氮氣進/出口的2升 2〇 3賴瓶中加人3-甲基-5-丙氧基嗟吩_2_魏酸(85.〇 g,424 mmolhN-琥拍醯亞胺(68.3 g,14當量)和二氯甲烷(7〇〇 mL),於室溫下攪拌。混合時放熱且溫度上升3。匚,生成一 種棕色溶液。冷浴内盛有室溫的水,只用於吸收輕微的放 熱。分4批每隔10分鐘加入26 〇 g固體#,#,_羰基二咪唑 -18· 200904811 (104 g,1.1當量)。每次添加都將出現2-3°C的升溫及氣體 的緩慢釋放。在最後一次添加完畢後,將該混合物於室溫 下攪拌3小時或攪拌過夜。用半飽和氣化銨(2〇〇 mL)終止該 混合物的反應並用水(3 X 150 mL)和鹽水(15〇 mL)洗滌。在 5 170 mbar和30°C的條件下,通過與庚烷的溶劑交換分離出 產物。生成固體後,先後將該混合物冷卻至室溫和5°C,即 得一種亮黃色固體’用濾布過濾分離,用庚烷洗滌,在玻 璃器皿内風乾20分鐘後再進一步真空乾燥(3〇 °c,1.5英寸 Hg),即得3-曱基-5-丙氧基噻吩-2-羧酸2,5-二氧吡咯烷-1-1〇 基酉旨(104 g,83%)。 4 NMR(CDC13,δ)6.20(1Η,s) ; 4.05(3H,t) ; 2.95(4H,s); 2.51(3H,s) ; 1.82(2H,m) ; l.〇5(3H,t)。 實例5 : 4-溴-3-曱基-5-丙氧基噻吩-2-羧酸2,5-二氧吡咯烷 15 -1-基酉旨 在設有熱電偶、冰浴和頂部攪拌的2升3頸圓底燒瓶 加入3-甲基-5-丙氧基噻吩-2-羧酸2,5-二氧吡咯烷-1-基酯 (81 g,273 mmol)、異丙烷(500 mL)和 DCM(350 mL),即得 一種非常稀的漿料。將該混合物冷卻至&lt; 5°C,在4至11 °C 2〇 的溫度範圍内以滴加方式加入溴(22 mL,328 mmol,1.2當 量)的庚烷(80 mL)溶液。將此很稀的漿料進一步稀釋,但該 混合物未完全均化。在一段19分鐘的時間内加入溶劑,待 反應完成時進行分析。用DCM(600 mL)稀釋反應物並用1# 硫代硫酸鈉(250 mL)終止反應。用水(2 X 350 mL)洗滌有機 200904811 層。此時HPLC分析顯示約有6.3%原料未反應。這大概是 由於原料附在玻璃器孤上,使它在溶液分析時未被測出。 將有機相乾燥(Na2S04)和濃縮(30°C,125mbar),即得一種 標色固體,將其再溶於DCM(700 mL)並於5°C用溴(4mL, 78 mmo卜0.3當量)的庚烧(2〇 mL)溶液處理以完成反應。將 有機相在250 mL 1 W硫代硫酸鈉(250 mL)水溶液中分配, 並用水(2 X 250 mL)和鹽水(250 mL)洗滌。將溶劑體積(30 °C’ 125 mbar)縮小至300 mL並加入400 mL庚烷(實現某種 程度的結晶)。通過旋轉蒸發將該混合物濃縮至乾,即得1〇4 g棕色固體。將粗製產物從回流IPA(500 mL)中再結晶並乾 燥(40 °C,1.5英寸Hg),即得93 g 4·溴-3-曱基-5-丙氧基噻 吩-2-羧酸2,5-二氧吡咯烷_ι_基酯,為褐色固體(91〇/〇)。 NMR(CDC13 ’ δ)4.19(2Η ’ t); 2.92(4H,s) ; 3.59(3H,s); 1.95(2H,m) ; 1.08(3H,t)。 實例6 : [4_(5_胺基曱基_2-氟苯基)_六氫吡啶小基]_(4_演_3· 甲基-5-丙氧基噻吩-2-基)_甲酮 在一個5升3頸圓底燒瓶中加入2,2,2•三氟_N_(4_氟_3_ 六氫吡啶-4-基苯曱基)-乙醯胺鹽酸鹽(176 7 g,〇 518 m〇1) 和1.51 L無水EtOH。攪拌該混合物並加入三乙胺(215 mL, 1.55 mol)。將該混合物攪拌3分鐘,然後加入4-溴-3-曱基 -5-丙氧基噻吩-2-羧酸2,5-二氧吡咯烷基酯(194 g,0.516 mol),放熱導致該混合物升溫至26。(:。將反應混合物攪拌 18小時’然後在I·5 L水和1.5 L TBME之間分配。依次用 -20- 200904811 水(2 x 0.5 L)、1 N HC1(0.5 L)水溶液和鹽水(0.2 L)洗滌有機 相。讓深琥珀色有機相通過一短Si02墊(h=0.5”,φ=3.5”) 過濾,用0.3 LEtOAc洗脫。未見顏色顯著減弱。將該溶液 冷卻至7°C,加入194 mL 50% NaOH水溶液,放熱導致該 5 混合物升溫至24°C。3小時後,依次用水(2 X 1 L,1 X 0.8 L) 和鹽水(0.5 L)洗滌該混合物,然後用硫酸鈉乾燥該有機相。 將該溶液冷卻至13°C,以滴加方式加入4 N HC1的1,4-二 噁烷溶液(135 mL,0.54 mol)。將該混合物攪拌3小時,然 後經過濾分離產物(相當緩慢),用MTBE洗滌並用空氣乾 ίο 燥15小時,即得130.2 g(50%)[4-(5-胺基曱基-2-氟苯基)- 六氮吼°定· 1 -基]-(4-漠-3 -甲基-5 -丙氧基嗟吩·2-基)-曱嗣’為 淡米黃色固體。 -21 -Dilute with THF. The mixture was cooled to ·22=f尧 bottle, and the n-butyl wire was added by adding a methane-burning solution of mL mW.4 equivalent) (the tearing method was quickly added, the temperature range was _22 to two. ' at 16 minutes Adding 1 hardened copper to the inside is freshly ground in a mortar and squeaked in the form of n-propanol poly-17- 5 14 c 'stable at about -21 ° C. Minutes 200904811 after 30 minutes 'maintains temperature At seven 〇 c卩, the reaction mixture was precipitated (d2〇 quenched) to show about 96% of the bellows. Carbon dioxide was bubbled into the mixture, and the gas flow was controlled to maintain the reaction temperature below _丨5.c. C 〇 was added until no more exotherm occurred and the reaction temperature began to decrease. The reaction was quenched with nitrous oxide in H 2 5 (_ mL) and EtOAc (50 g) was weighed. The mixture was stirred for 30 minutes and filtered with a cloth. 0.5 #NaOH (3 〇 洗 洗 饼 。 。 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽 遽When the solution is formed with a thick color/black tar, the solution is smeared with a cloth to obtain a lightly plucked filtrate. The pH value of the solution is adjusted to 4.5 即. The amount of brown sinking hall, using filter, cloth transition, washing with ice water (10 0 m L) 'air drying in glassware and drying with vacuum coal box (12 hours '30〇C '1.3 mbar)' is 3_ Methyl _5_propoxy. Cefone_2 carboxylic acid, as a beige solid (81.1 g, 80 〇 / 〇). NMR CCD Ch &gt; δ) 6.12 (1 Η &gt;s); 4.02 (3H &gt;t; 2.49(3H » s); is 1·82(2Η,m) ; 1.05(3H,t). Example 4: 2-mercapto-5-propoxy porphin-2-decanoic acid 2,5-dioxopyrrolidine ester was provided in 2 liters with top Hertz, cold, thermocouple and nitrogen inlet/outlet 2〇3 lyophilized with 3-methyl-5-propoxy porphin-2-furic acid (85.〇g, 424 mmolhN-sodium bromide (68.3 g, 14 equivalents) and dichloromethane (7 〇〇 mL), stirring at room temperature. When mixing, it exotherms and the temperature rises by 3. 匚, a brown solution is formed. The cold bath contains room temperature water, which is only used to absorb a slight exotherm. Add 26 〇g solid #,#, _ carbonyl diimidazole-18· 200904811 (104 g, 1.1 eq.) every 10 minutes. 2-3 ° C temperature rise and slow gas release will occur for each addition. After the addition was completed, the mixture was stirred at room temperature for 3 hours or stirred overnight. The reaction of the mixture was quenched with half-saturated ammonium sulfate (2 mL) and water (3 X 150 mL) and brine (15 mL) Washing. The product was isolated by solvent exchange with heptane at 5 170 mbar and 30 ° C. After solid formation, the mixture was cooled to room temperature and 5 ° C successively to give a bright yellow solid. The cloth was separated by filtration, washed with heptane, air-dried in a glassware for 20 minutes, and then further vacuum dried (3 ° C, 1.5 inches Hg) to obtain 3-mercapto-5-propoxythiophene-2-carboxylic acid. 2,5-Dioxypyrrolidine-1-1 fluorenyl (104 g, 83%) 4 NMR (CDC13, δ) 6.20 (1 Η, s); 4.05 (3H, t); 2.95 (4H, s 2.51(3H,s); 1.82(2H,m) ; l.〇5(3H,t) Example 5: 4-bromo-3-indolyl-5-propoxythiophene-2-carboxylic acid 2 ,5-Dioxypyrrolidine 15 -1-ylindole is intended to be added to a 2-liter 3-neck round bottom flask equipped with a thermocouple, ice bath and top stir. 3-Methyl-5-propoxythiophene-2-carboxylic acid 2,5-Dioxapyrrolidin-1-yl ester (81 g, 273 mmol), isopropane (500 mL) and DCM (350 mL) gave a very dilute slurry. The mixture was cooled to &lt; At 5 ° C, a solution of bromine (22 mL, 328 mmol, 1.2 eq.) in heptane (80 mL) was added dropwise at a temperature of 4 to 11 ° C. The diluted salt was further diluted. , but the mixture was not completely homogenized. The solvent was added over a period of 19 minutes and analyzed when the reaction was completed. The reaction was diluted with DCM (600 mL) and 1# thiosulfur The reaction was quenched with sodium acetate (250 mL). EtOAc &lt;RTI ID=0.0&gt;&gt; This is probably due to the fact that the material is attached to the glass so that it is not detected during solution analysis. The organic phase was dried (Na.sub.2SO.sub.4) and concentrated (30[deg.] C. The heptane (2 〇 mL) solution was treated to complete the reaction. The organic phase was partitioned between 250 mL of 1 W sodium sulphate (250 mL) and washed with water (2 X 250 mL) and brine (250 mL). Reduce the solvent volume (30 °C '125 mbar) to 300 mL and add 400 mL of heptane (to achieve some degree of crystallization). The mixture was concentrated to dryness by rotary evaporation to give a brown solid. The crude product was recrystallized from refluxing IPA (500 mL) and dried (40 ° C, 1.5 inch Hg) to give 93 g of 4-bromo-3-indolyl-5-propoxythiophene-2-carboxylic acid 2 , 5-dioxypyrrolidine, i.e., a brown solid (91 〇/〇). NMR (CDC13' δ) 4.19 (2 Η s); 2.92 (4H, s); 3.59 (3H, s); 1.95 (2H, m); 1.08 (3H, t). Example 6: [4_(5-Aminoguanidino-2-fluorophenyl)-hexahydropyridine small group]_(4_演_3·Methyl-5-propoxythiophen-2-yl)-A Ketone in a 5 liter, 3-neck round bottom flask with 2,2,2•trifluoro_N_(4_fluoro_3_hexahydropyridin-4-ylbenzoinyl)-acetamide hydrochloride (176 7 g) , 〇518 m〇1) and 1.51 L of anhydrous EtOH. The mixture was stirred and triethylamine (215 mL, 1.55 mol) was added. The mixture was stirred for 3 minutes and then 2,5-dioxapyrrolidinyl 4-bromo-3-indolyl-5-propoxythiophene-2-carboxylate (194 g, 0.516 mol) was added. The mixture was warmed to 26. (:. Stir the reaction mixture for 18 hours' then distribute between 1·5 L of water and 1.5 L of TBME. Use -20-200904811 water (2 x 0.5 L), 1 N HCl (0.5 L) in water and brine ( 0.2 L) Wash the organic phase. The dark amber organic phase was filtered through a short SiO 2 pad (h = 0.5 s, φ = 3.5 s) and eluted with 0.3 L of EtOAc. No significant color reduction was observed. The solution was cooled to 7°. C, adding 194 mL of 50% aqueous NaOH solution, the exotherm causes the mixture to warm to 24 ° C. After 3 hours, the mixture is washed with water (2 X 1 L, 1 X 0.8 L) and brine (0.5 L), then used The organic phase was dried over sodium sulfate. The solution was cooled to <RTI ID=0.0></RTI> to <RTI ID=0.0></RTI> <RTIgt; </RTI> <RTIgt; The product was isolated by filtration (substantially slow), washed with MTBE and dried with air for 15 hours to give 130.2 g (50%) of [4-(5-aminomercapto-2-fluorophenyl)-hexazaindole · 1 -yl]-(4-di-3-methyl-5-propoxy porphin-2-yl)-曱嗣' is a pale beige solid. -21 -

Claims (1)

200904811 十、申請專利範圍: L ~種製備[4-(5-胺基曱基-2-氟苯基)-六氫吼啶_1_ 基](4-&gt;臭-3-曱基-5-丙氧基°塞吩-2-基)-曱嗣的方法,包 括以下步驟: 10 使4-溴-3-甲基-5-丙氧基噻吩-2-羧酸2,5-二氧吡咯 烷-1-基酯與2,2,2-三氟-N-(4-氟-3·六氫吡啶-4-基 笨甲基)-乙醯胺鹽酸鹽和強鹼或叔胺驗在醇溶劑 中發生醯胺化偶合反應,以生成2,2,2-三敗 ~^-{3-[1-(4-溴-3-曱基-5-丙氧基嗟吩-2-幾基)_六 氫吡啶-4-基]-4-氟-笨曱基}_乙醯胺;以及 用鹼使2,2,2·三氟-Ν-{3-[1-(4-溴-3-甲基-5-丙氧基 噻吩-2-羰基)-六氫吡啶_4_基]_4_氟_苯甲基卜乙醯 胺脫保護,以生成[4-(5-胺基曱基_2_氟苯基六氫 比疋1-基]-(4-/臭-3-甲基_5_丙氧基0塞吩_2_基)_甲 酮。 2. 如申請專利範圍第i項之方法,#中用㈣胺化偶合反 應的醇溶劑是乙醇。 20 3. 4. Ϊ申請專·㈣1項之方法,其中賴胺化偶合反應 疋於約室溫至約取的溫度條件下進行的。 如申請專利範圍第1項之太、、土 ^ ^ ^ 匚产 Μ疋方法,其中用於醯胺化偶合 反應的驗是三乙胺。 5. 如申請專利範圍第1項之方法 溶液NaOH水溶液進行的。 其中脫保護是用驗的水 6. 如申請專利範圍第1項之方法 其中脫保護是於約5°C -22· 200904811 至約30°C的溫度條件下進行的。 -23- 200904811 七、指定代表圖: (一) 本案指定代表圖為:第(無)圖。 (二) 本代表圖之元件符號簡單說明: 無。 10 八、本案若有化學式時,請揭示最能顯示發明特徵的化學式: 無。 20200904811 X. Patent application scope: L ~ species preparation [4-(5-aminomercapto-2-fluorophenyl)-hexahydroacridin-1-yl] (4-> odor-3-mercapto-5 -Propoxy °ephen-2-yl)-oxime, comprising the steps of: 10 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo Pyrrolidin-1-yl ester and 2,2,2-trifluoro-N-(4-fluoro-3·hexahydropyridin-4-yl-p-methyl)-acetamide hydrochloride and strong base or tertiary amine Amidoximation coupling reaction occurs in an alcohol solvent to form 2,2,2-tris-(^-{3-[4-(4-bromo-3-indolyl-5-propoxy porphin-2) -monoyl)-hexahydropyridin-4-yl]-4-fluoro-azainyl}-acetamide; and 2,2,2·trifluoro-Ν-{3-[1-(4) with a base -Bromo-3-methyl-5-propoxythiophene-2-carbonyl)-hexahydropyridine_4_yl]_4_fluoro-benzylideneamine deprotected to form [4-(5- Aminoguanidino-2-fluorophenyl hexahydropyridin-1-yl]-(4-/odor-3-methyl-5-propoxy0-cetyl-2-yl)-methanone. For the method of claim i, the alcohol solvent used in the (4) amination coupling reaction is ethanol. 20 3. 4. The method of application (4), wherein the lysine coupling reaction is about room temperature to about Take For example, in the case of the patent application, the method for the production of the hydrazine coupling reaction is triethylamine. The method of the solution is carried out in a solution of aqueous NaOH. The deprotection is the water used in the test. 6. The method of claim 1 wherein the deprotection is carried out at a temperature of about 5 ° C -22 · 200904811 to about 30 ° C -23- 200904811 VII. Designation of representative drawings: (1) The representative representative of the case is: (No). (2) The symbol of the symbol of the representative figure is simple: None. 10 8. If there is a chemical formula in this case Please reveal the chemical formula that best shows the characteristics of the invention: None. 20
TW097111154A 2007-03-29 2008-03-28 Use of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester for preparing the tryptase inhibitor [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone TW200904811A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90884407P 2007-03-29 2007-03-29

Publications (1)

Publication Number Publication Date
TW200904811A true TW200904811A (en) 2009-02-01

Family

ID=39535396

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097111154A TW200904811A (en) 2007-03-29 2008-03-28 Use of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester for preparing the tryptase inhibitor [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone

Country Status (3)

Country Link
AR (1) AR065858A1 (en)
TW (1) TW200904811A (en)
WO (1) WO2008121666A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20151338T1 (en) * 2008-08-22 2016-01-15 Sanofi [4- (5-AMINOMETHYL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL] - [7-FLUORO-1- (2-METHOXY-ETHYL) -4TRIFLUOROMETOXY-1H-INDOL-3-IL] METHANONE AS INHIBITOR MASTOCYT TRIPTASES
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
JP5787977B2 (en) 2010-04-08 2015-09-30 レスピバート・リミテツド P38 MAP kinase inhibitor
EP2582700B1 (en) 2010-06-17 2016-11-02 Respivert Limited Respiratory formulations containing p38 mapk inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2005000039A (en) * 2004-03-26 2005-10-31 Aventis Pharma Inc HYDROCHLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) - PIPERIDIN-1-IL] - (4-BOMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE

Also Published As

Publication number Publication date
WO2008121666A1 (en) 2008-10-09
AR065858A1 (en) 2009-07-08

Similar Documents

Publication Publication Date Title
JP6284928B2 (en) Process for making hydroxylated cyclopentylpyrimidine compounds
KR20170029501A (en) Process for the preparation of 4-alkoxy-3-hydroxypicolinic acids
TW201029975A (en) Process for manufacturing substituted 3-pyridylmethyl ammonium bromides
TW200904811A (en) Use of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester for preparing the tryptase inhibitor [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone
WO2022002116A1 (en) Preparation method for phenylisoxazoline compound
CN109956906A (en) A kind of preparation method for disliking La Geli key intermediate
CN104918912B (en) Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds
CN1849320A (en) Method for preparing renzapride and intermediates thereof
JP2010535185A (en) Method for producing alfuzosin hydrochloride
CN1231482C (en) Preparation methods of thiazolidinedione derivatives and intermediates
CN109485567B (en) Clean preparation method of 4-hydroxymethylthiazole and intermediate thereof
WO2001064683A1 (en) Processes for the production of thienopyrimidine derivatives
TW200904810A (en) 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester, its regio-specific synthesis and intermediate thereto
CN102675385A (en) Preparation method for doxorubicin13-position hydrazone derivative
TW200902510A (en) Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid
JP2001316391A (en) Method for producing thienopyridine derivative
KR100893756B1 (en) Efficient Manufacturing Method of Montelukast
JP3998925B2 (en) Method for producing 3,3,3-trifluoro-2-hydroxypropionic acid derivative
US7304158B2 (en) Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone)
JP4675234B2 (en) Intermediate for producing optically active quinolonecarboxylic acid derivative and process for producing the same
JP2019014716A (en) Process for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound and synthetic intermediate thereof
CN116425685A (en) A kind of synthetic method of elagolix sodium impurity
CN119954778A (en) A method for synthesizing lenacapvir sodium and its series of intermediate compounds
JP4788049B2 (en) Dicarboxylic acid diester derivative and method for producing the same
JP4752121B2 (en) Method for producing nitrile derivative, intermediate thereof and method for producing intermediate